AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31517396 — intervention group
Group type: EXPERIMENTAL
Intervention: Renin
Number of subjects: 16
Study 31517396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphotoxin alpha 1: beta 2
Number of subjects: 16
Study 30058345 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg·kg‐1)
Number of subjects: 13
Study 30058345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 28319755 — intervention group
Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 10
Study 28319755 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 10
Study 26051546 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional method (custom tray with impression compound and silicone)
Number of subjects: 24
Study 26051546 — intervention group
Group type: COMPARATOR
Intervention: Simplified method (stock tray and alginate)
Number of subjects: 24
Study 23620504 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chih (TCC)
Number of subjects: 63
Study 23620504 — intervention group
Group type: COMPARATOR
Intervention: Health Education Control (HEC)
Number of subjects: 63
Study 20171049 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented acetabular components
Number of subjects: 215
Study 20171049 — intervention group
Group type: COMPARATOR
Intervention: Uncemented acetabular components
Number of subjects: 215
Study 20171049 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral cases
Number of subjects: 215
Study 20171049 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral hip arthropathy
Number of subjects: 215
Study 20171049 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral hip impairment, knee or spine problems, or significant comorbidities
Number of subjects: 215
Study 16988203 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast 500 microg (2 x 250 microg) after a high-fat meal
Number of subjects: 12
Study 16988203 — intervention group
Group type: COMPARATOR
Intervention: Roflumilast 500 microg (2 x 250 microg) after overnight fasting
Number of subjects: 12
Study 14734879 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula (reduced total protein concentration enriched in bovine alpha-lactalbumin)
Number of subjects: 193
Study 14734879 — intervention group
Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 193
Study 14734879 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula
Number of subjects: 193
Study 11587609 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin (0.4 mg/mL, 2 mL solution applied for 2 minutes)
Number of subjects: 24
Study 11587609 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride (placebo, equal volume applied for 2 minutes)
Number of subjects: 24
Study 9156373 — intervention group
Group type: EXPERIMENTAL
Intervention: sirolimus (0.5‐6.5 mg/m2/12 hr)
Number of subjects: 40
Study 8181025 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 0
Study 8181025 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 3331375 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC)
Number of subjects: 66
Study 3331375 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TAM)
Number of subjects: 66
Study 3331375 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) and Tamoxifen (TAM)
Number of subjects: 66
Study 31588902 — intervention group
Group type: EXPERIMENTAL
Intervention: RiksmatenFlexDiet
Number of subjects: 78
Study 31588902 — intervention group
Group type: COMPARATOR
Intervention: Recall interviews
Number of subjects: 78
Study 28259853 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiation of a cough management algorithm
Number of subjects: 214
Study 28259853 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 214
Study 26321102 — intervention group
Group type: EXPERIMENTAL
Intervention: Step-wise model of diabetes prevention
Number of subjects: 602
Study 26321102 — intervention group
Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 602
Study 23370582 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based exercise (at least twice-weekly for 8 weeks)
Number of subjects: 29
Study 23370582 — intervention group
Group type: COMPARATOR
Intervention: Control group (no water-based exercise)
Number of subjects: 29
Study 21223307 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol use
Number of subjects: 393
Study 21223307 — intervention group
Group type: EXPERIMENTAL
Intervention: Impulsivity (IMP)
Number of subjects: 393
Study 21223307 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety sensitivity (AS) and anxiety
Number of subjects: 393
Study 18445608 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexed lateral position
Number of subjects: 82
Study 18445608 — intervention group
Group type: COMPARATOR
Intervention: Sitting position
Number of subjects: 82
Study 17132552 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive post-acute neuropsychological rehabilitation
Number of subjects: 50
Study 17132552 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-rehabilitated)
Number of subjects: 50
Study 14767412 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 9
Study 14767412 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 9
Study 10689260 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide
Number of subjects: 9406
Study 10689260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9406
Study 10689260 — intervention group
Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 9406
Study 10689260 — intervention group
Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 9406
Study 10689260 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsmokers
Number of subjects: 9406
Study 9337826 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 100 micrograms b.i.d
Number of subjects: 8
Study 9337826 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 200 micrograms b.i.d
Number of subjects: 8
Study 9337826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 100 micrograms b.i.d
Number of subjects: 8
Study 9337826 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone 200 micrograms b.i.d
Number of subjects: 8
Study 9337826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 8408733 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinidine sulfate (200 mg orally)
Number of subjects: 10
Study 8408733 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg orally)
Number of subjects: 10
Study 8408733 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine-quinidine combination
Number of subjects: 10
Study 3760461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (5 mg/day for 5 days)
Number of subjects: 10
Study 3760461 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3760461 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 10
Study 31912198 — intervention group
Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D concentration in children with islet autoimmunity (18 months prior to first seroconversion)
Number of subjects: 732
Study 31912198 — intervention group
Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D concentration in children with type 1 diabetes (18 months prior to first seroconversion)
Number of subjects: 732
Study 31912198 — intervention group
Group type: COMPARATOR
Intervention: Serum 25-hydroxyvitamin D concentration in children with type 1 diabetes (at calendar age of 12 months)
Number of subjects: 732
Study 30333336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (3 g in 100 ml saline solution)
Number of subjects: 70
Study 30333336 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (placebo, 100 ml)
Number of subjects: 70
Study 26592763 — intervention group
Group type: EXPERIMENTAL
Intervention: Fidaxomicin
Number of subjects: 0
Study 26592763 — intervention group
Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 0
Study 24892729 — intervention group
Group type: EXPERIMENTAL
Intervention: Toupet procedure
Number of subjects: 42
Study 24892729 — intervention group
Group type: COMPARATOR
Intervention: Dor procedure
Number of subjects: 42
Study 22349673 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine-propofol-dexmedetomidine combination (KPD group, n = 30)
Number of subjects: 60
Study 22349673 — intervention group
Group type: COMPARATOR
Intervention: Ketamine-propofol combination (KP group, n = 30)
Number of subjects: 60
Study 20170424 — intervention group
Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 203
Study 20170424 — intervention group
Group type: COMPARATOR
Intervention: Intramedullary fixation
Number of subjects: 203
Study 17509069 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (100 mg daily)
Number of subjects: 780
Study 17509069 — intervention group
Group type: COMPARATOR
Intervention: Metformin (titrated to 2000 mg daily)
Number of subjects: 780
Study 17509069 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 780
Study 17509069 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 780
Study 15708043 — intervention group
Group type: EXPERIMENTAL
Intervention: Clean intermittent catheterization
Number of subjects: 132
Study 15708043 — intervention group
Group type: COMPARATOR
Intervention: Control group (150 controls, 90 men and 60 women)
Number of subjects: 132
Study 12424384 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate doses of alcohol
Number of subjects: 0
Study 9523805 — intervention group
Group type: COMPARATOR
Intervention: 2.5 ml 2% lidocaine in 7.5% glucose
Number of subjects: 90
Study 9523805 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% prilocaine in 7.5% glucose
Number of subjects: 90
Study 9523805 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine in 7.5% glucose
Number of subjects: 90
Study 7915501 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms twice daily)
Number of subjects: 159
Study 2672786 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (0.3 mg/kg per dose, administered at 8 AM and 12 PM on school days)
Number of subjects: 10
Study 2672786 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 10
Study 1103209 — intervention group
Group type: EXPERIMENTAL
Intervention: marihuana containing 20 mg Delta‐9‐tetrahydrocannabinol
Number of subjects: 72
Study 1103209 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 72
Study 31504596 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone gel for 12 months
Number of subjects: 790
Study 31504596 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel for 12 months
Number of subjects: 790
Study 26897544 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal group therapy intervention
Number of subjects: 26
Study 27562434 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec (IDeg)
Number of subjects: 13
Study 27562434 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (IGla)
Number of subjects: 13
Study 25241220 — intervention group
Group type: EXPERIMENTAL
Intervention: ILR strategy (n = 39)
Number of subjects: 78
Study 25241220 — intervention group
Group type: COMPARATOR
Intervention: Conventional evaluation strategy (CONV group, n = 39)
Number of subjects: 78
Study 23040521 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose arginine (500 mg · kg(‐1) · d(‐1))
Number of subjects: 12
Study 23040521 — intervention group
Group type: COMPARATOR
Intervention: Low-dose arginine (100 mg · kg(‐1) · d(‐1)) combined with sodium phenylbutyrate (500 mg · kg(‐1) · d(‐1))
Number of subjects: 12
Study 20500044 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 354
Study 20500044 — intervention group
Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 354
Study 20500044 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher potency statins
Number of subjects: 354
Study 20500044 — intervention group
Group type: COMPARATOR
Intervention: Lower potency statins
Number of subjects: 354
Study 20500044 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenge
Number of subjects: 354
Study 17426000 — intervention group
Group type: EXPERIMENTAL
Intervention: Cephalothin V (2.0 g) intravenous 30 min before the operation
Number of subjects: 72
Study 17426000 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone injection (6-10 ml ozone at 40 microg/ml) into the discs and 10 ml ozone into the paravertebral space
Number of subjects: 72
Study 17426000 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 72
Study 15668261 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy (RT)
Number of subjects: 435
Study 15668261 — intervention group
Group type: COMPARATOR
Intervention: No axillary treatment
Number of subjects: 435
Study 15668261 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 435
Study 12195173 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental device (hearing aids)
Number of subjects: 720
Study 10071005 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of individual trials with deliberately introduced heterogeneity
Number of subjects: 0
Study 10071005 — intervention group
Group type: EXPERIMENTAL
Intervention: Combining observational data
Number of subjects: 0
Study 10071005 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study 7879930 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine low dose (targeting plasma concentration of 0.15 ng/ml)
Number of subjects: 24
Study 7879930 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine medium dose (targeting plasma concentration of 0.30 ng/ml)
Number of subjects: 24
Study 7879930 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine high dose (targeting plasma concentration of 0.45 ng/ml)
Number of subjects: 24
Study 7879930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 2071729 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental self‐quitting guide emphasizing nicotine fading and other nonaversive behavioral strategies
Number of subjects: 2021
Study 2071729 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐quitting guide with a support guide for the quitter's family and friends
Number of subjects: 2021
Study 2071729 — intervention group
Group type: EXPERIMENTAL
Intervention: Self‐quitting and support guides along with four brief counselor calls
Number of subjects: 2021
Study 2071729 — intervention group
Group type: COMPARATOR
Intervention: Control guide providing motivational and quit tips and referral to locally available guides and programs
Number of subjects: 2021
Study 6666612 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromassage
Number of subjects: 0
Study 6666612 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 31958177 — intervention group
Group type: EXPERIMENTAL
Intervention: Worked examples highlighting salient features
Number of subjects: 65
Study 31958177 — intervention group
Group type: EXPERIMENTAL
Intervention: Worked examples highlighting discriminatory features
Number of subjects: 65
Study 31958177 — intervention group
Group type: COMPARATOR
Intervention: Historical controls (medical students interpreting ECG rhythms without worked examples)
Number of subjects: 65
Study 30711062 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive group (n = 948) received $30 per call for up to five calls and $40 for biochemically verified abstinence at 6 months.
Number of subjects: 1900
Study 30711062 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 952) did not receive financial incentives.
Number of subjects: 1900
Study 29716077 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-quantum noise randomized cipher based on amplified spontaneous emission (ASE) light source employing Y-00 protocol
Number of subjects: 0
Study 26814038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 3 mcg · kg(‐1) plus oral placebo (Group IN DEX)
Number of subjects: 0
Study 26814038 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate 50 mg · kg(‐1) plus intranasal saline placebo (Group CH)
Number of subjects: 0
Study 26814038 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 0
Study 26814038 — intervention group
Group type: COMPARATOR
Intervention: Oral chloral hydrate
Number of subjects: 0
Study 26922170 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed and bevacizumab maintenance therapy
Number of subjects: 110
Study 26922170 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed maintenance therapy
Number of subjects: 110
Study 23887135 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-narrative blogs with health-related similarities
Number of subjects: 150
Study 23887135 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative blogs
Number of subjects: 150
Study 23887135 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-narrative blogs
Number of subjects: 150
Study 21289261 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of progesterone
Number of subjects: 8
Study 21289261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 19204582 — intervention group
Group type: EXPERIMENTAL
Intervention: HJ‐151 pedometer
Number of subjects: 47
Study 19204582 — intervention group
Group type: EXPERIMENTAL
Intervention: HJ‐720ITC pedometer
Number of subjects: 47
Study 19204582 — intervention group
Group type: COMPARATOR
Intervention: HJ‐720ITC at the backpack position
Number of subjects: 47
Study 19204582 — intervention group
Group type: EXPERIMENTAL
Intervention: HJ‐151 and HJ‐720ITC pedometers
Number of subjects: 47
Study 16707870 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing gum (salivary stimulation) for 30 min after immersion in cola drink
Number of subjects: 9
Study 16707870 — intervention group
Group type: COMPARATOR
Intervention: No treatment (erosion only)
Number of subjects: 9
Study 16707870 — intervention group
Group type: COMPARATOR
Intervention: Brushing immediately after immersion (0 min)
Number of subjects: 9
Study 16707870 — intervention group
Group type: COMPARATOR
Intervention: Brushing after 60 min
Number of subjects: 9
Study 16707870 — intervention group
Group type: COMPARATOR
Intervention: Fluoride dentifrice brushing
Number of subjects: 9
Study 16707870 — intervention group
Group type: COMPARATOR
Intervention: Erosion only
Number of subjects: 9
Study 15013894 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily patching (> or =2 hours a day) combined with at least 1 hour of near activities
Number of subjects: 66
Study 11709795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral washes using a PCR detection system based on Pneumocystis major surface glycoprotein primers
Number of subjects: 175
Study 11709795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral washes using a PCR detection system based on mitochondrial large subunit rRNA primers
Number of subjects: 175
Study 11709795 — intervention group
Group type: COMPARATOR
Intervention: Induced sputum positive for Pneumocystis
Number of subjects: 175
Study 11709795 — intervention group
Group type: COMPARATOR
Intervention: Bronchoalveolar lavage (BAL) samples
Number of subjects: 175
Study 9041342 — intervention group
Group type: EXPERIMENTAL
Intervention: 40‐microg S subunit vaccine
Number of subjects: 46
Study 9041342 — intervention group
Group type: COMPARATOR
Intervention: 10‐microg S subunit vaccine
Number of subjects: 46
Study 9041342 — intervention group
Group type: COMPARATOR
Intervention: mixed particle vaccine (pre‐S1, pre‐S2, and S subunit particles)
Number of subjects: 46
Study 7613114 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 ppb NO2
Number of subjects: 16
Study 7613114 — intervention group
Group type: COMPARATOR
Intervention: Air
Number of subjects: 16
Study 2152972 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH(4-9) analogue, Org 2766 (high dose: 1 mg/m²)
Number of subjects: 55
Study 2152972 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH(4-9) analogue, Org 2766 (low dose: 0.25 mg/m²)
Number of subjects: 55
Study 2152972 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 497303 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyridoxine
Number of subjects: 6
Study 497303 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 6
Study 497303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30503602 — intervention group
Group type: EXPERIMENTAL
Intervention: RAPP contact group
Number of subjects: 494
Study 30503602 — intervention group
Group type: COMPARATOR
Intervention: Non-RAPP contact group
Number of subjects: 494
Study 28476154 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent Girls Empowerment Programme (AGEP)
Number of subjects: 10000
Study 28476154 — intervention group
Group type: EXPERIMENTAL
Intervention: Health voucher and bank account (additional components of AGEP)
Number of subjects: 10000
Study 25136884 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 207
Study 25136884 — intervention group
Group type: COMPARATOR
Intervention: Endeavor zotarolimus-eluting stents (ZES)
Number of subjects: 207
Study 25136884 — intervention group
Group type: COMPARATOR
Intervention: Resolute zotarolimus-eluting stents (ZES)
Number of subjects: 207
Study 23278328 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated bolus group
Number of subjects: 102
Study 23278328 — intervention group
Group type: COMPARATOR
Intervention: Infusion group
Number of subjects: 102
Study 21291333 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Number of subjects: 572
Study 21291333 — intervention group
Group type: COMPARATOR
Intervention: Insulin lispro
Number of subjects: 572
Study 19881458 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Number of subjects: 24
Study 19881458 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 24
Study 16740528 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating pressure mattresses
Number of subjects: 1971
Study 16740528 — intervention group
Group type: COMPARATOR
Intervention: Alternating pressure overlays
Number of subjects: 1971
Study 15577788 — intervention group
Group type: EXPERIMENTAL
Intervention: Envoy System (totally implantable middle ear device)
Number of subjects: 7